Safety, pharmacokinetics, and antiviral activity of a combination of TMB-365 and TMB-380 in people living with HIV suppressed with antiretroviral therapy in the USA: a phase 1b/2a, open-label, dose-escalation study

The Lancet HIV · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles